Determination of antimicrobial susceptibility patterns and inducible clindamycin resistance in Staphylococcus aureus strains recovered from southeastern Turkey

Journal of Microbiology, Immunology and Infection

Volumn 44, Issue 1, 2011, Pages 57-62

  Eksi, Fahriye ^a   Gayyurhan, Efgan Dogan ^a   Bayram, Aysen ^a   Karsligil, Tekin ^a  

^a GAZIANTEP UNIVERSITY   (Turkey)

Author keywords

Antibiotic susceptibility; Inducible clindamycin resistance; Staphylococcus aureus

Indexed keywords

CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; LINEZOLID; METICILLIN; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; DISK DIFFUSION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; STAPHYLOCOCCUS AUREUS; TURKEY (BIRD); DRUG EFFECTS; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; TRANSCRIPTION INITIATION; TURKEY;

ANTI-BACTERIAL AGENTS; CLINDAMYCIN; DISK DIFFUSION ANTIMICROBIAL TESTS; DRUG RESISTANCE, BACTERIAL; HUMANS; PREVALENCE; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TRANSCRIPTIONAL ACTIVATION; TURKEY;

EID: 79952250595     PISSN: 16841182     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmii.2011.01.011     Document Type: Article

References (40)

1. Kim H.B., Jang H.C., Nam H.J., Lee Y.S., Kim B.S., Park W.B., et al. In vitro activities of 28 antimicrobial agents against Staphylococcus aureus isolates from tertiary-care hospitals in Korea: a nationwide survey. Antimicrob Agents Chemother 2004, 48:1124-1127.
2. Hussain F.M., Boyle-Vavra S., Bethel C.D., Daum R.S. Current trends in community-acquired methicillin-resistant Staphylococcus aureus at a tertiary care pediatric facility. Pediatr Infect Dis J 2000, 19:1163-1166.
3. Groom A.V., Wolsey D.H., Naimi T.S., Smith K., Johnson S., Boxrud D., et al. Community-acquired methicillin-resistant Staphylococcus aureus in a rural American Indian community. JAMA 2001, 286:1201-1205.
4. Fiebelkorn K.R., Crawford S.A., McElmeel M.L., Jorgensen J.H. Practical disc diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J Clin Microbiol 2003, 41:4740-4744.
5. Lim J.A., Kwon A.E., Kim S.K., Cong Y., Lee K., Choi E.C. Prevalence of resistance to macrolide, lincosamide and streptogramin antibiotics in Gram-positive cocci isolated in Korean hospital. J Antimicrob Chemother 2002, 49:489-495.
6. Drinkovic D., Fuller E.R., Shore K.P., Holland D.J., Ellis-Pegler R. Clindamycin treatment of Staphylococcus aureus expressing inducible clindamycin resistance. J Antimicrob Chemother 2001, 48:315-316.
7. Roberts M.C., Sutcliffe J., Courvalin P., Jensen L.B., Rood J., Seppala H. Nomenclature for macrolide-lincosamide-streptogramin B resistance determinants. Antimicrob Agents Chemother 1999, 43:2823-2830.
8. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis 2002, 34:482-492.
9. Siberry G.K., Tekle T., Carroll K., Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003, 37:1257-1260.
10. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement M100-S15 2005, CLSI, Wayne, PA.
11. Garner J.S., Jarvis W.R., Emori T.G., Horan T.C., Hughes J.M. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988, 16:128-140.
12. Waldvogel F.A. Staphylococcus aureus (including staphylococcal toxic shock). Mandell, Douglas and Bennett's principles and practice of infectious diseases 2000, 2069. CV, A Harcourt Health Sciences Co, Philadelphia, PA. 5th ed. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
13. Diekema D.J., Pfaller M.A., Schmitz F.J., Smayevsky J., Bell J., Jones R.N., et al. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001, 32(Suppl. 2):114-132.
14. Baysal B., Tuncer I, Erayman B., Arslan U. Susceptibility of clinical isolates of Staphylococcus aureus to fusidic acid and various antibiotics. Infek Derg 2003, 17:27-30.
15. Vardar-Ünlü G., Ünlü M., Yaĝmuroĝlu A. Mupirocin resistance of Staphylococcus aureus and coagulase-negative Staphylococci isolated from clinical specimens. ANKEM Derg 2006, 20:222-225.
16. Cetinkol Y., Altindiş M., Çetinkaya Z., Aktepe O.C. Determination of methicillin resistance in staphylococci with different methods and detection of multiple antibiotic resistance. Mikrobiyol Bül 2008, 42:119-124.
17. Baddour M.M., Abuelkheir M.M., Fatani A.J. Trends in antibiotic susceptibility patterns and epidemiology of MRSA isolates from several hospitals in Riyadh, Saudi Arabia. Ann Clin Microbiol Antimicrob 2006, 5:30.
18. Hussain W., Ikram A., Butt T., Faraz A., Hussain A., Wiqar M.A. In vitro susceptibility pattern of Staphylococcus aureus clinical isolates at Rawalpindi. Pak J Pathol 2008, 19:12-15.
19. Blandino G., Marchese A., Ardito F., Fadda G., Fontana R., Lo Cascio G., et al. Antimicrobial susceptibility profiles of Pseudomonas aeruginosa and Staphylococcus aureus isolated in Italy from patients with hospital-acquired infections. Int J Antimicrob Agents 2004, 24:515-518.
20. Sader H.S., Streit J.M., Fritsche T.R., Jones R.N. Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centers: results of the Daptomycin Surveillance Programme (2002-2004). Clin Microbiol Infect 2006, 12:844-852.
21. Borg M.A., de Kraker M., Scicluna E., van de Sande-Bruinsma N., Tiemersma E., Monen J., et al. Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in invasive isolates from southern and eastern Mediterranean countries. J Antimicrob Chemother 2007, 60:1310-1315. ARMed Project members and collaborators.
22. Stratchounski L.S., Dekhnich A.V., Kretchikov V.A., Edelstain I.A., Narezkina A.D., Afinogenov G.E., et al. Antimicrobial resistance of nosocomial strains of Staphylococcus aureus in Russia: results of a prospective study. J Chemother 2005, 17:54-60.
23. Coombs G.W., Nimmo G.R., Bell J.M., Huygens F., O'Brien F.G., Malkowski M.J., et al. Australian Group for Antimicrobial Resistance: Genetic diversity among community methicillin-resistant Staphylococcus aureus strains causing outpatient infections in Australia. J Clin Microbiol 2004, 42:4735-4743.
24. Shrestha B., Pokhrel B.M., Mohapatra T.M. Phenotypic characterization of nosocomial isolates of Staphylococcus aureus with reference to MRSA. J Infect Dev Ctries 2009, 3:554-560.
25. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement M100-S19 2009, CLSI, Wayne, PA.
26. Entenza J.M., Drugeon H., Glauser M.P., Moreillon P. Treatment of experimental endocarditis due to erythromycin-susceptible or resistant methicillin-resistant Staphylococcus aureus with RP 59500. Antimicrob Agents Chemother 1995, 39:1419-1424.
27. Tsiodras S., Gold H.S., Sakoulas G., Ellopoulos G.M., Wennersten C., Venkataraman L., et al. Linezolid resistance in a clinical isolates of Staphylococcus aureus. Lancet 2001, 358:207-208.
28. Wilson P., Andrews J.A., Charlesworth R., Walesby R., Singer M., Farrell D.J., et al. Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 2003, 51:186-188.
29. Ayliffe G.A.J. The progressive intercontinental spread of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1997, 24(Suppl. 1):S74-S79.
30. Frank A.L., Marcinak J.F., Mangat P.D., Tjhio J.T., Kelkar S., Screckenberger P.C., et al. Clindamycin treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J 2002, 21:530-534.
31. Ladhani S., Garbash M. Staphylococcal skin infections in children: rational drug therapy recommendations. Pediatr Drugs 2005, 7:77-102.
32. Fokas S., Fokas S., Tsironi M., Kalkani M., Dionysopouloy M. Prevalence of inducible clindamycin resistance in macrolide-resistant Staphylococcus spp. Clin Microbiol Infect 2005, 11:337-340.
33. Rahbar M., Hajia M. Inducible clindamycin resistance of Staphylococcus aureus2: a cross-sectional report. Pak J Biol Sci 2007, 10:189-192.
34. Yilmaz G., Aydin K., Iskender S., Caylan R., Koksal I. Detection and prevalence of inducible clindamycin resistance in staphylococci. J Med Microbiol 2007, 56:342-345.
35. Delialioglu N., Aslan G., Ozturk C., Baki V., Sen S., Emekdas G. Inducible clindamycin resistance in Staphylococci isolated from clinical samples. Jpn J Infect Dis 2005, 58:104-106.
36. Schmitz F.J., Sadurski R., Kray A., Boos M., Geisel R., Köhrer K., et al. Prevalence of macrolide-resistance genes in Staphylococcus aureus and Enterococcus faecium isolates from 24 European university hospitals. J Antimicrob Chemother 2000, 45:891-894.
37. Lina G., Quaglia A., Reverdy M.E., Leclercq R., Vandenesch F., Etienne J. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci. Antimicrob Agents Chemother 1999, 43:1062-1066.
38. Melter O., Aires de Sous M., Urbaskova P., Jakubu V., Zemliskova H., Lencastre H. Update on the major clonal types of methicillin-resistant Staphylococcus aureus in the Czech Republic. J Clin Microbiol 2003, 41:4998-5005.
39. Schreckenberger P.C., Illendo E., Ristow K.L. Incidence of constitutive and inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci in a community and tertiary care hospital. J Clin Microbiol 2004, 42:2777-2779.
40. Lim H.S., Lee H., Roh K.H., Yum J.H., Yong D., Lee K., et al. Prevalence of inducible clindamycin resistance in Staphylococcal isolates at a Korean tertiary care hospital. Yonsei Med J 2006, 47:480-484.